May Chin Lim brings over 13 years of experience providing accounting advisory services to public and private companies of all sizes with a current focus in the life sciences industry including medical device, pharmaceutical, and biotechnology.
May Chin held numerous finance interim management role at biotech companies at various stages of life cycle and has extensive experience overseeing the financial reporting preparatory work for public offerings at both the US and Hong Kong capital markets. She is proficient in complex technical accounting matters, SEC reporting including recurring filings, debt, and equity financing transactions and stock compensation under both US GAAP and IFRS (International Financial Reporting Standards) frameworks.
Prior to joining CFGI, May Chin was an Audit Manager at Ernst & Young Australia and the US. May Chin is a Chartered Accountant and a member of Chartered Accountants Australia & New Zealand. She graduated with a Bachelor of Commerce (Accounting) from the University of Adelaide, Australia.